Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Why this Tennessee special election has the 'whole world' watching - 2Monetary Versatility: Get ready for Life's Unforeseen Difficulties
- 3Audits of 6 Specialty Mixed drinks
- 4Shredded cheese recall: Multiple brands sold at Aldi, Target and Walmart affected over potential metal fragment contamination
- 5Vote In favor of Your Favored Shimmering Water
- A Republican elected governor in California? It's not as far-fetched as it sounds.
- 4 injured in suburban Philadelphia nursing home explosion file negligence lawsuit
- ByHeart baby formula from all lots may be contaminated with botulism bacteria, tests show
- The Delight of Camper Vans: Choosing the One That Meets Your Requirements
- A definitive Manual for Internet Mastering and Expertise Improvement
- Triple polar vortex to plunge central and eastern U.S. into Arctic cold through mid-December
- Atorvastatin recall may affect hundreds of thousands of patients – and reflects FDA’s troubles inspecting medicines manufactured overseas
- 2 bright planets light up April evenings — here's where and when to look
- Israel faces tough choices over haredi draft exemptions, legal expert warns
